MRSN
USDMersana Therapeutics Inc. Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$9.065
Kõrge
$9.065
Madal
$8.000
Maht
0.03M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
40.7M
Tööstusharu
Biotehnoloogia
Riik
United States
Kauplemisstatistika
Keskmine maht
0.07M
Börs
NMS
Valuuta
USD
52 nädala vahemik
Seotud uudised
Truist Securities Maintains Buy on Mersana Therapeutics, Adjusts Price Target To $36 from $250
Truist Securities analyst Asthika Goonewardene maintains Mersana Therapeutics with a Buy, Adjusts Target to $36 from $250
Guggenheim Maintains Buy on Mersana Therapeutics, Lowers Price Target to $30
Guggenheim analyst Michael Schmidt maintains Mersana Therapeutics with a Buy and lowers the price target from $125 to $30.
Mersana Therapeutics, Inc. (MRSN) Q2 2025 Earnings Call Transcript
Mersana Therapeutics, Inc. (MRSN) Q2 2025 Earnings Call Transcript
Mersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial Results
More than 45 patients enrolled in Emi-Le Phase 1 dose expansion cohorts in post-topoisomerase-1 inhibitor ADC (post-topo-1) triple-negative breast cancer (TNBC)Plan to report initial clinical data from Emi-Le expansion
Mersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025
CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers
Seotud aktsiad
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.